Anika Therapeutics, Inc., a prominent player in osteoarthritis pain management and regenerative solutions, based in Bedford, Mass., shared news of granting 3,138 restricted stock units (RSUs) on April 1, 2026, to a newly hired non-executive employee. The grant, part of the 2021 Inducement Plan, was approved by the compensation committee of the board of directors under Nasdaq Listing Rule 5635(c)(4) to entice the grantee to join the company.